Selvarajah, A.; van der Heijden, D.J.; Remkes, W.S.; ten Berg, J.M.; Magro, M.; von Birgelen, C.; Riezebos, R.K.; Pisters, R.; Hemels, M.E.W.; Rasoul, S.;
et al. Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry. J. Clin. Med. 2025, 14, 4401.
https://doi.org/10.3390/jcm14134401
AMA Style
Selvarajah A, van der Heijden DJ, Remkes WS, ten Berg JM, Magro M, von Birgelen C, Riezebos RK, Pisters R, Hemels MEW, Rasoul S,
et al. Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry. Journal of Clinical Medicine. 2025; 14(13):4401.
https://doi.org/10.3390/jcm14134401
Chicago/Turabian Style
Selvarajah, Abi, Dirk J. van der Heijden, Wouter S. Remkes, Jurriën M. ten Berg, Michael Magro, Clemens von Birgelen, Robert K. Riezebos, Ron Pisters, Martin E. W. Hemels, Saman Rasoul,
and et al. 2025. "Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry" Journal of Clinical Medicine 14, no. 13: 4401.
https://doi.org/10.3390/jcm14134401
APA Style
Selvarajah, A., van der Heijden, D. J., Remkes, W. S., ten Berg, J. M., Magro, M., von Birgelen, C., Riezebos, R. K., Pisters, R., Hemels, M. E. W., Rasoul, S., van ‘t Hof, A. W. J., Somi, S., Polad, J., Hoogslag, P., & Hermanides, R. S.
(2025). Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry. Journal of Clinical Medicine, 14(13), 4401.
https://doi.org/10.3390/jcm14134401
